Viridian Therapeutics (STU:1S1) FCF Margin % : -101,495.65% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Viridian Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Viridian Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was €-70.03 Mil. Viridian Therapeutics's Revenue for the three months ended in Dec. 2024 was €0.07 Mil. Therefore, Viridian Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -101,495.65%.

As of today, Viridian Therapeutics's current FCF Yield % is -25.82%.

The historical rank and industry rank for Viridian Therapeutics's FCF Margin % or its related term are showing as below:

STU:1S1' s FCF Margin % Range Over the Past 10 Years
Min: -77214.34 Med: -1331.81 Max: -216.78
Current: -77214.34

During the past 13 years, the highest FCF Margin % of Viridian Therapeutics was -216.78%. The lowest was -77214.34%. And the median was -1331.81%.

STU:1S1's FCF Margin % is ranked worse than
97.33% of 1011 companies
in the Biotechnology industry
Industry Median: -127.22 vs STU:1S1: -77214.34

Viridian Therapeutics FCF Margin % Historical Data

The historical data trend for Viridian Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics FCF Margin % Chart

Viridian Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-2,840.44

-1,853.66

-5,339.81

-58,926.04

-77,205.90

Viridian Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-52,863.64	-63,037.88	-63,862.69	-79,224.68	-101,495.65

Competitive Comparison of Viridian Therapeutics's FCF Margin %

For the Biotechnology subindustry, Viridian Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viridian Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Viridian Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Viridian Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-222.353	/	0.288
	=	-77,205.90 %

Viridian Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-70.032	/	0.069
	=	-101,495.65 %

Viridian Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (STU:1S1) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VRDN:USA 0K1R:UK 1S1:Germany

Address

221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453

Website

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Headlines

No Headlines